Head-to-head · WeighScore
NuvaHealth vs RestorLife Med
The verdict
NuvaHealth takes it — 74.2/100 to 65.3/100.
NuvaHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuvaHealth (nuvahealth.org) is a LegitScript-certified compounded GLP-1 telehealth platform offering compounded semaglutide starting at $159 first-month and compounded tirzepatide starting at $259 first-month.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NuvaHealth | RestorLife Med |
|---|---|---|
| WeighScore | 74.2/100 | 65.3/100 |
| Grade | C | C |
| Scorecard rank | #65 | #222 |
| Semaglutide | $139/mo (first-month rate, compounded) | $199/mo (6-month plan, compounded) |
| Tirzepatide | $229/mo (first-month rate, compounded) | Not disclosed |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #65 · C
Strengths
- LegitScript Certified seal displayed on the marketing site (the standard third-party telehealth/pharmacy accreditation)
- Free and fast delivery + 24/7 patient support disclosed on the home page
- Newark, DE address suggests a US-incorporated entity (vs offshore)
- $139 first-month price for compounded semaglutide injection is among the cheapest in the US compounded telehealth market
- $229 first-month price for compounded tirzepatide injection sits in the lower-median range
Where it loses points
- Standard ongoing monthly price NOT publicly disclosed (gated behind checkout) — patients should ask for the maintenance-dose price before committing
- Specific legal entity name + state of incorporation NOT publicly disclosed on the home page — material YMYL transparency gap
- Pharmacy partners NOT publicly named — material YMYL transparency gap
- Per-state availability NOT enumerated; verify your state ships before purchase
- Lab work + coaching support NOT publicly disclosed
Graded #222 · C
Strengths
- Verifiable LegitScript certification (seal ID 50400451) plus a named board-certified physician (Dr. Michael Wasef, MD) licensed in all 50 states
- Full GLP-1 lineup: compounded semaglutide and tirzepatide, plus gentler microdose entry options
- Generous support — unlimited care-team messaging, monthly check-ins, dosage adjustments, and 1 free blood test per quarter on the GLP-1 protocols
- Available in all 50 states with free priority shipping, discreet packaging, and roughly 48-hour delivery
- Transparent multi-month pricing with 50% off your first month; semaglutide protocols are compounded with B12
Where it loses points
- The advertised $299 is a struck-through anchor price, not a starting point: the real month-to-month rate is $299, a first month runs $149 at 50% off, and the $199 rate needs six months
- The page states its pricing is 'introductory and subject to change', so none of these figures is committed to
- The tirzepatide price is published the same way, against a struck-through anchor, and we could not establish which figure a buyer actually pays
- A separate semaglutide microdose is sold at $99/mo — a sub-therapeutic protocol, not a cheaper weight-loss dose
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.